Opinion|Videos|January 29, 2025
Integrating Revumenib Into Current R/R AML Treatment Paradigms
Panelists discuss key findings from the phase I/II study of the all-oral SAVE combination with revumenib in relapsed/refractory acute monocytic leukemia (R/R AML), the impact of the regimen's success in achieving high response and MRD negativity rates on integrating all-oral therapies into the treatment paradigm for R/R AML, particularly in patients with prior venetoclax or transplant exposure, and the potential role of revumenib in current treatment paradigms for R/R AML.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. LeBlanc to ask Dr. Goldberg: Briefly comment on the key findings presented from the Pphase I/II study of the all-oral “SAVE” combination with revumenib in R/R AML.
(Issa, GC, et al. ASH 2024. Oral Abstract 216, Session: 616 or pg. 13) - Dr. LeBlanc to ask Dr. Blachly: How does the success of the SAVE regimen in achieving high response and MRD negativity rates influence the integration of all-oral therapies into the treatment paradigm for R/R AML, particularly in patient populations with prior venetoclax or transplant exposure?
- Dr. LeBlanc to ask GROUP: Where do you see revumenib fitting in your current treatment paradigms for R/R AML?
Advertisement
Related to this article
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
4
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
5